Makulaödem bei Uveitis – Steroide oder VEGF-Inhibitoren?

Zusammenfassung

Das Makulaödem ist eine der häufigsten zu einer dauerhaften und irreversiblen Reduktion des Sehvermögens führende Komplikation im Krankheitsverlauf einer Uveitis. Durch die optische Kohärenztomografietechnologie (OCT-Technologie) und die Fluoreszenzangiografie (FAG) kann das Makulaödem häufiger detektiert werden. Makulaödeme finden sich in unterschiedlichsten morphologischen Variationen auch bei Uveitisaugen und können bei jeder Form der Uveitis auftreten. Nachfolgend muss dann auch konsequent behandelt werden. Während Makulaödeme bei aktiver Inflammation meist sehr gut auf eine entzündungshemmende systemische Therapie reagieren, trifft dies für Makulaödeme bei klinisch reizfreien Augen häufig nicht zu. Nach den aktuellen Behandlungsempfehlungen sollten Dexamethasonimplantate, die sowohl die aktive Inflammation als auch das Makulaödem reduzieren, als 1. intravitreale Therapie genutzt werden. An 2. Stelle kommen Vascular-endothelial-Growth-Factor-Inhibitoren (VEGF-Inhibitoren) zum Einsatz. Bei der Wahl des Therapeutikums sind neben dem Entzündungsgrad auch die bisherigen Komplikationen, wie ein Glaukom, und auch die Komplikationsrate der gewählten Therapie, wie Augeninnendrucksteigerung und Kataraktinduktion, zu beachten, sodass bei Vorliegen entsprechender Kontraindikationen VEGF-Inhibitoren auch das Therapeutikum der ersten Wahl sein können. Mit beiden intravitrealen Wirkstoffgruppen kann eine Besserung des Makulaödems erzielt werden.

Abstract

Macular edema in uveitis patients is certainly the most frequent complication leading to a permanent and irreversible reduction in vision during the course of the disease. Thanks to optical coherence tomography (OCT) technology and fluorescein angiography (FAG), significantly more macular edemas are detected. Macular edema can be found in various uveitis varieties and can show different clinical patterns. All macular edema should be treated. Macular edema with active inflammation usually reacts very well to general uveitis treatment. In the case of eyes without visible inflammation, however, the response to such therapy is usually less effective. According to the latest treatment recommendations, dexamethasone implants should be used as the first intravitreal therapy. Vascular endothelial growth factor inhibitors (VEGF inhibitors) are second-line treatment regimens. The choice of therapy is, therefore, primarily based on the degree of inflammation and the individual complications, such as glaucoma, lens situation or previous increase in IOP after steroid administration. These individual complications may allow using VEGF inhibitors as first line treatment. An improvement in the macular edema can be achieved with both groups of active substances.

Schlüsselwörter

Uveitis - Makulaödem - Kortikosteroide - VEGF-Inhibitoren

Key words

uveitis - macular edema - corticosteroids - VEGF inhibitors

• Literatur

• 1 Mackensen F, Baydoun L, Garweg J. et al. Uveitis intermedia: Leitlinie der Deutschen Ophthalmologischen Gesellschaft e.V. und des Berufsverbandes der Augenärzte Deutschlands e.V. Ophthalmologe 2014; 111: 1033-1040
• 2 Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augenärzte Deutschlands. Leitlinie des Berufsverbands der Augenärzte Deutschlands e.V. und der Deutschen Ophthalmologischen Gesellschaft: Leitlinie Nr. 14: Uveitis anterior (Stand: Oktober 2010). 2010 Im Internet: http://www.dog.org/?cat=32 Stand: 10.01.2017
• 3 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005; 140: 509-516
• 4 Dick AD, Tundia N, Sorg R. et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 2016; 123: 655-662
• 5 Rothova A, Suttorp-van Schulten MS, Frits Treffers W. et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80: 332-336
• 6 Jones NP. The Manchester uveitis clinic: The first 3000 patients, 2: Uveitis manifestations, complications, medical and surgical management. Ocul Immunol Inflamm 2015; 23: 127-134
• 7 Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006; 113: 1446-1449
• 8 Tomkins-Netzer O, Talat L, Bar A. et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology 2014; 121: 2387-2392
• 9 Levin MH, Pistilli M, Daniel E. et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 2014; 121: 588-595
• 10 Kempen JH, Sugar EA, Jaffe GJ. et al. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology 2013; 120: 1852-1859
• 11 Ossewaarde-van Norel J, Camfferman LP, Rothova A. Discrepancies between fluorescein angiography and optical coherence tomography in macular edema in uveitis. Am J Ophthalmol 2012; 154: 233-239
• 12 Kim M, Kwon HJ, Choi EY. et al. Correlation between fluorescein angiographic findings and visual acuity in Behçet retinal vasculitis. Yonsei Med J 2015; 56: 1087-1096
• 13 Munk MR, Bolz M, Huf W. et al. Morphologic and functional evaluations during development, resolution, and relapse of uveitis-associated cystoid macular edema. Retina 2013; 33: 1673-1683
• 14 Ossewaarde-van Norel J, Berg EM, Sijssens KM. et al. Subfoveal serous retinal detachment in patients with uveitic macular edema. Arch Ophthalmol 2011; 129: 158-162
• 15 Tran TH, de Smet MD, Bodaghi B. et al. Uveitic macular oedema: Correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br J Ophthalmol 2008; 92: 922-927
• 16 Szepessy Z, Barsi A, Nemeth J. Macular changes correlate with the degree of acute anterior uveitis in patients with spondyloarthropathy. Ocul Immunol Inflamm 2016; 24: 153-158
• 17 Balaskas K, Ballabeni P, Guex-Crosier Y. Retinal thickening in hla-b27-associated acute anterior uveitis: Evolution with time and association with severity of inflammatory activity. Invest Ophthalmol Vis Sci 2012; 53: 6171-6177
• 18 Lehpamer B, Moshier E, Pahk P. et al. Epiretinal membranes in uveitic macular edema: Effect on vision and response to therapy. Am J Ophthalmol 2014; 157: 1048-1055
• 19 Tranos PG, Tsaousis KT, Vakalis AN. et al. Long-term follow-up of inflammatory cystoid macular edema. Retina 2012; 32: 1624-1628
• 20 Curnow SJ, Falciani F, Durrani OM. et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 2005; 46: 4251-4259
• 21 Ooi KG, Galatowicz G, Towler HM. et al. Multiplex cytokine detection versus elisa for aqueous humor: Il-5, Il-10, and IFN-gamma profiles in uveitis. Invest Ophthalmol Vis Sci 2006; 47: 272-277
• 22 Van Kooij B, Rothova A, Rijkers GT. et al. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 2006; 142: 192-194
• 23 Paroli MP, Teodori C, DʼAlessandro M. et al. Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. Eur J Ophthalmol 2007; 17: 938-942
• 24 Fine HF, Baffi J, Reed GF. et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001; 132: 794-796
• 25 Weiss K, Steinbrugger I, Weger M. et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye 2009; 23: 1812-1818
• 26 Jeon S, Lee WK, Jung Y. Changes in the intraocular cytokine levels after intravitreal bevacizumab in uveitic macular edema. Ocul Immunol Inflamm 2012; 20: 360-364
• 27 Noma H, Funatsu H, Yamasaki M. et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008; 22: 42-48
• 28 Heiligenhaus A, Bertram B, Heinz C. et al. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur intravitrealen Therapie des Makulaödems bei Uveitis. Ophthalmologe 2014; 111: 740-748
• 29 Schilling H, Heiligenhaus A, Laube T. et al. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 2005; 25: 182-188
• 30 Sen HN, Vitale S, Gangaputra SS. et al. Periocular corticosteroid injections in uveitis: Effects and complications. Ophthalmology 2014; 121: 2275-2286
• 31 Roesel M, Gutfleisch M, Heinz C. et al. Einfluss von intravitrealem und parabulbärem Triamcinolon Acetonid auf die intraokulare Entzündung bei aktiver nicht infektiöser Uveitis. Klin Monatsbl Augenheilkd 2009; 226: 110-114
• 32 Grajewski RS, Zurek-Imhoff B, Roesel M. et al. Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis. Acta Ophthalmol 2012; 90: 657-662
• 33 Lowder C, Belfort jr. R, Lightman S. et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
• 34 Sorkin N, Loewenstein A, Habot-Wilner Z. et al. Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies. Ophthalmologica 2014; 232: 83-91
• 35 Khurana RN, Bansal AS, Chang LK. et al. Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis. Retina 2016; DOI: 10.1097/IAE.0000000000001406.
• 36 Cao JH, Mulvahill M, Zhang L. et al. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology 2014; 121: 1871-1876
• 37 Pelegrín L, de la Maza MS, Molins B. et al. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye 2015; 29: 943-950
• 38 Callanan DG, Jaffe GJ, Martin DF. et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: Three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191-1201
• 39 Multicenter Uveitis Steroid Treatment Trial Research Group. Kempen JH, Altaweel MM, Holbrook JT. et al Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: The multicenter uveitis steroid treatment trial. Ophthalmology 2011; 118: 1916-1926
• 40 Jaffe GJ, Lin P, Keenan RT. et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: Two-year results. Ophthalmology 2016; 123: 1940-1948
• 41 Lott MN, Schiffman JC, Davis JL. Bevacizumab in inflammatory eye disease. Am J Ophthalmol 2009; 148: 711-717.e2
• 42 Mansour AM, Arevalo JF, Fardeau C. et al. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol 2012; 47: 269-274
• 43 Cordero Coma M, Sobrin L, Onal S. et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007; 114: 1574-1579.e1
• 44 Mackensen F, Heinz C, Becker MD. et al. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study. Retina 2008; 28: 41-45
• 45 Ziemssen F, Deuter CM, Stuebiger N. et al. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (avastin). Graefes Arch Clin Exp Ophthalmol 2007; 245: 917-918
• 46 Reddy AK, Cabrera M, Yeh S. et al. Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: Twelve-month outcomes. Retina 2014; 34: 2431-2438
• 47 Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148: 303-309
• 48 Soheilian M, Rabbanikhah Z, Ramezani A. et al. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: A randomized pilot study. J Ocul Pharmacol Ther 2010; 26: 199-206
• 49 Rahimi M, Shahrzad SS, Banifatemi M. Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema. Iran J Immunol 2012; 9: 136-144
• 50 Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011; 31: 111-118
• 51 Sen HN, Abreu FM, Louis TA. et al. Cataract surgery outcomes in uveitis: The multicenter uveitis steroid treatment trial. Ophthalmology 2016; 123: 183-190
• 52 Kiddee W, Trope GE, Sheng L. et al. Intraocular pressure monitoring post intravitreal steroids: A systematic review. Surv Ophthalmol 2013; 58: 291-310
• 53 Malclès A, Dot C, Voirin N. et al. Safety of intravitreal dexamethasone implant (ozurdex): The safodex study. Incidence and risk factors of ocular hypertension. Retina 2016; DOI: 10.1097/IAE.0000000000001369.
• 54 Tomkins-Netzer O, Taylor SRJ, Bar A. et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology 2014; 121: 1649-1654
• 55 Habot-Wilner Z, Sorkin N, Goldenberg D. et al. Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema. Ophthalmologica 2014; 232: 77-82
• 56 Breitbach M, Rack D, Dietzel M. et al. Intravitreales Dexamethason-Implantat zur Behandlung des therapierefraktären zystoiden Makulaödems bei nicht infektiöser Uveitis. Klin Monatsbl Augenheilkd 2016; 233: 601-605
• 57 Khurana RN, Porco TC. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema. Retina 2015; 35: 1640-1646
• 58 Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ. et al. Intravitreal bevacizumab in refractory uveitic macular edema: One-year follow-up. Eur J Ophthalmol 2009; 19: 622-629
• 59 Al-Dhibi H, Hamade IH, Al-Halafi A. et al. The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema. J Ophthalmol 2014; 2014: 729465